OTTAWA, Nov. 30 /CNW/ - MDS Nordion, a leading provider of medical
isotopes and radiopharmaceuticals, has provided an update to their medical
isotope customers about a temporary supply issue. MDS Nordion has received
information from their primary supplier regarding an interruption in the
supply of molybdenum-99 used in the manufacturing of technetium-99m generators
and iodine-131. The primary supplier has advised MDS Nordion that a scheduled
reactor maintenance shutdown has been extended to complete an upgrade to the
electrical system, addressing a technical regulatory issue.
MDS Nordion's primary supplier is working closely with their regulator,
the Canadian Nuclear Safety Commission, to finalize and complete
implementation of their upgrade plan. At the same time, MDS Nordion is working
closely with their global supply network to mitigate the impact of this
temporary supply issue on their customers. Based on our current information,
an approval of the upgrade plan is anticipated shortly with a targeted return
to full production in mid-December. The impact of this interruption is
currently expected to reduce EBITDA by up to approximately US $4 million in
the first quarter of 2008.
About MDS Nordion
MDS Nordion (www.mdsnordion.com) is a world leader in medical isotopes,
radiation and related technologies. It is a business unit of MDS Inc.
(TSX:MDS)(NYSE: MDZ). MDS Inc. is a global life sciences company that provides
market-leading products and services for the development of drugs and
diagnosis and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS Inc. has more than
6,200 highly skilled people in 28 countries. Find out more at www.mdsinc.com
or by calling 1-888-MDS-7222, 24 hours a day.
This document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects", "anticipates", "plans",
"intends", "indicates", "targeted" or similar expressions. The statements are
not a guarantee of future impact or performance and are inherently subject to
risks and uncertainties. The actual impact to the Company of the maintenance
shutdown could differ materially from that currently anticipated due to a
number of factors, including, the actual timing of a return to full production
and other risk factors identified in other documents filed by the Company with
Canadian and US securities regulatory authorities from time to time.
For further information:
For further information: Media: Shelley Maclean, Manager External
Communications, MDS Nordion, (613) 592-3400 ext. 2414,
email@example.com; Investors: Sharon Mathers, Senior Vice-President,
Investor Relations and External Communications, MDS Inc., (416) 675-6777 x